Ojemba is an oral, brain-penetrant, highly-selective type II RAF kinas inhibitor designed to target a key enzyme in the MAPK signaling pathway. Ojemda is the first FDA-approved systemic therapy for pediatric LGG patients with BRAF rearrangements, including fusions.